Clinical Trial Update: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating how BRAF and PIK3K status influences efficacy of FOLFIRI + bevacizumab or cetuximab in RAS wild-type metastatic colorectal cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer Metastasis

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: COMPLETED